Turkiye Klinikleri Journal of Dermatology

.: ORIGINAL RESEARCH
Fecal Calprotectin Level in Patients with Rosacea: Gut Inflammation May Be Associated with the Type of Rosacea, A Case-Control Study
Rozasea Hastalarında Fekal Kalprotektin Düzeyi: Bağırsak İltihabı Rozasea Tipi ile İlişkili Olabilir, Bir Vaka-Kontrol Çalışması
Havva Hilal AYVAZa, Mümtaz Cem ŞİRİNb, Seda ATAYc, Selma KORKMAZa, İjlal ERTURANa, Rahime Cankat DOĞANTEKİNa, Mehmet YILDIRIMa
aDepartment of Dermatology, Süleyman Demirel University Faculty of Medicine, Isparta, Türkiye
bDepartment of Medical Microbiology, Süleyman Demirel University Faculty of Medicine, Isparta, Türkiye
cClinic of Dermatology, Eskişehir City Hospital, Eskişehir, Türkiye
Turkiye Klinikleri J Dermatol. 2022;32(1):1-8
doi: 10.5336/dermato.2021-85699
Article Language: EN
Full Text
ABSTRACT
Objective: Rosacea is a chronic inflammatory skin disease that has complex pathogenesis. The association between rosacea and inflammatory gastrointestinal tract disorders is a popular topic, and fecal calprotectin is a potential marker to diagnose intestinal inflammation of any cause. In this study, the aims were to determine the relationship between disease type, disease severity, and fecal calprotectin levels in patients with rosacea, and also compare the calprotectin levels between healthy controls and rosacea patients. Material and Methods: Forty-six patients with rosacea, and sex-age-matched 92 healthy volunteers were enrolled in this study. Calprotectin levels of stool samples were calculated using enzymelinked immunosorbent assay. Results: Of these patients, 30 (65.2%) had erythematotelangiectatic type rosacea, and 16 (34.8%) had papulopustular type rosacea. There was not a statistically significant difference between the mean fecal calprotectin levels of the patient and control groups (p=0.414), whereas the mean fecal calprotectin levels of the erythematotelangiectatic type group was lower than the papulopustular type group, and this difference was significant (p<0.001). Conclusion: According to the results, the underlying pathogenesis of different types of rosacea may be different, and the papulopustular type of rosacea may be more related to gut inflammation. In addition, we think that fecal calprotectin may be useful in evaluating intestinal inflammation especially in patients with papulopustular type and severe rosacea.

Keywords: Rosacea; gastrointestinal tract; inflammation
ÖZET
Amaç: Rozasea, karmaşık patogenezi olan kronik inflamatuar bir deri hastalığıdır. Rozasea ve inflamatuar gastrointestinal sistem bozuklukları arasındaki ilişki popüler bir konudur ve fekal kalprotektin, herhangi bir nedene bağlı intestinal inflamasyonu teşhis etmek için kullanılan potansiyel bir belirteçtir. Bu çalışmada, rozasealı hastalarda hastalık tipi, hastalık şiddeti ile fekal kalprotektin düzeyleri arasındaki ilişkiyi ve sağlıklı kontrollerle farkını belirlemek amaçlandı. Gereç ve Yöntemler: Bu çalışmaya rozasealı 46 hasta ve cinsiyet-yaş uyumlu 92 sağlıklı gönüllü alındı. Dışkı örneklerinin kalprotektin seviyeleri, enzime bağlı immünosorbent tahlili kullanılarak hesaplandı. Bulgular: Bu hastaların 30'unda (%65,2) eritematotelanjiektatik tip rozasea, 16'sında (%34,8) papülopüstüler tip rozasea vardı. Hasta ve kontrol gruplarının ortalama fekal kalprotektin düzeyleri arasında istatistiksel olarak anlamlı fark bulunmazken (p=0,414); eritematotelanjiektatik tip hastalığı olan grubun ortalama fekal kalprotektin düzeyleri papülopüstüler tip grubuna göre daha düşüktü ve bu fark anlamlıydı (p<0.001). Sonuç: Elde edilen sonuçlara göre farklı rozasea türlerinin altta yatan patogenezi farklı olabilir ve papülopüstüler tip rozasea daha çok bağırsak iltihabı ile ilişkili olabilir. Ayrıca özellikle papülopüstüler tip ve şiddetli rozasealı hastalarda, fekal kalprotektinin intestinal inflamasyonun değerlendirilmesinde faydalı olabileceğini düşünmekteyiz.

Anahtar Kelimeler: Rozasea; gastrointestinal kanal; inflamasyon
REFERENCES:
  1. Rainer BM, Fischer AH, Luz Felipe da Silva D, Kang S, Chien AL. Rosacea is associated with chronic systemic diseases in a skin severity-dependent manner: results of a case-control study. J Am Acad Dermatol. 2015;73(4):604-8. [Crossref]  [PubMed] 
  2. Gupta AK, Chaudhry MM. Rosacea and its management: an overview. J Eur Acad Dermatol Venereol. 2005;19(3):273-85. [Crossref]  [PubMed] 
  3. Two AM, Wu W, Gallo RL, Hata TR. Rosacea: Part I. Introduction, categorization, histology, pathogenesis, and risk factors. J Am Acad Dermatol. 2015;72(5):749-58; quiz 759-60. [Crossref]  [PubMed] 
  4. Weiss E, Katta R. Diet and rosacea: the role of dietary change in the management of rosacea. Dermatol Pract Concept. 2017;7(4):31-7. [Crossref]  [PubMed]  [PMC] 
  5. Kendall SN. Remission of rosacea induced by reduction of gut transit time. Clin Exp Dermatol. 2004;29(3):297-9. [Crossref]  [PubMed] 
  6. Woo YR, Lim JH, Cho DH, Park HJ. Rosacea: molecular mechanisms and management of a chronic cutaneous inflammatory condition. Int J Mol Sci. 2016;17(9):1562. [Crossref]  [PubMed]  [PMC] 
  7. Wu CY, Chang YT, Juan CK, Shieh JJ, Lin YP, Liu HN, et al. Risk of inflammatory bowel disease in patients with rosacea: Results from a nationwide cohort study in Taiwan. J Am Acad Dermatol. 2017;76(5):911-7. [Crossref]  [PubMed] 
  8. Ayling RM, Kok K. Fecal calprotectin. Adv Clin Chem. 2018;87:161-90. [Crossref]  [PubMed] 
  9. Seo SC, Ahn SH, Ri S, Yoon Y, Byeon JH, Kim SH, et al. Elevated fecal calprotectin levels are associated with severity of atopic dermatitis in children. Asian Pac J Allergy Immunol. 2018;36(2):82-7. [PubMed] 
  10. Premjeyanth V, Shipman AR, Shipman KE. Faecal calprotectin in dermatology practice. Clin Exp Dermatol. 2020;45(7):831-5. [Crossref]  [PubMed] 
  11. Aksu Çerman A, Aktaş Karabay E, Kaya HE, Türe Özdemir F, Özkur E, Erdem Y, et al. Evaluation of fecal calprotectin as a marker of gastrointestinal inflammation in rosacea: A case-control study. Dermatol Ther. 2021;34(3): e14946. [Crossref]  [PubMed] 
  12. Wilkin J, Dahl M, Detmar M, Drake L, Feinstein A, Odom R, et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46(4):584-7. [Crossref]  [PubMed] 
  13. Wilkin J, Dahl M, Detmar M, Drake L, Liang MH, Odom R, et al; National Rosacea Society Expert Committee. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2004;50(6):907-12. [Crossref]  [PubMed] 
  14. Ellis SR, Nguyen M, Vaughn AR, Notay M, Burney WA, Sandhu S, et al. The skin and gut microbiome and its role in common dermatologic conditions. Microorganisms. 2019;7(11): 550. [Crossref]  [PubMed]  [PMC] 
  15. Nam JH, Yun Y, Kim HS, Kim HN, Jung HJ, Chang Y, et al. Rosacea and its association with enteral microbiota in Korean females. Exp Dermatol. 2018;27(1):37-42. [Crossref]  [PubMed] 
  16. Wang FY, Chi CC. Association of rosacea with inflammatory bowel disease: A MOOSE-compliant meta-analysis. Medicine (Baltimore). 2019;98(41):e16448. [Crossref]  [PubMed]  [PMC] 
  17. Papoutsopoulou S, Satsangi J, Campbell BJ, Probert CS. Review article: impact of cigarette smoking on intestinal inflammation-direct and indirect mechanisms. Aliment Pharmacol Ther. 2020;51(12):1268-85. [Crossref]  [PubMed] 
  18. Cosnes J. What is the link between the use of tobacco and IBD? Inflamm Bowel Dis. 2008;14 Suppl 2:S14-5. Erratum in: Inflamm Bowel Dis. 2009;15(9):1438-47. [Crossref]  [PubMed] 
  19. Berkowitz L, Schultz BM, Salazar GA, Pardo-Roa C, Sebastián VP, Álvarez-Lobos MM, et al. Impact of cigarette smoking on the gastrointestinal tract inflammation: opposing effects in Crohn's disease and ulcerative colitis. Front Immunol. 2018;9:74. [Crossref]  [PubMed]  [PMC] 
  20. Egeberg A, Weinstock LB, Thyssen EP, Gislason GH, Thyssen JP. Rosacea and gastrointestinal disorders: a population-based cohort study. Br J Dermatol. 2017;176(1):100-6. [Crossref]  [PubMed] 
  21. Spoendlin J, Karatas G, Furlano RI, Jick SS, Meier CR. Rosacea in patients with ulcerative colitis and crohn's disease: a population-based case-control study. Inflamm Bowel Dis. 2016;22(3):680-7. [Crossref]  [PubMed] 
  22. O'Neill CA, Monteleone G, McLaughlin JT, Paus R. The gut-skin axis in health and disease: A paradigm with therapeutic implications. Bioessays. 2016;38(11):1167-76. [Crossref]  [PubMed] 
  23. Yilmaz K, Altindis M, Dikicier BS, Yüksekal G, Köroglu M. Is there a relationship between rosacea with gut dysbiosis? Dermatol Sin. 2020;38(2):88-93. [Crossref] 
  24. D'Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(12):2218-24. [Crossref]  [PubMed] 
  25. Costa F, Mumolo MG, Ceccarelli L, Bellini M, Romano MR, Sterpi C, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut. 2005;54(3):364-8. [Crossref]  [PubMed]  [PMC] 
  26. Wang S, Song R, Wang Z, Jing Z, Wang S, Ma J. S100A8/A9 in Inflammation. Front Immunol. 2018;9:1298. [Crossref]  [PubMed]  [PMC] 
  27. Eşer E, Engin B, Yüksel P, Kocazeybek BS, Kutlubay Z, Serdaroğlu S, et al. Relationship between fecal calprotectin level and disease activity in patients with hidradenitis suppurativa. Dermatol Ther. 2020;33(2):e13232. [Crossref]  [PubMed] 
  28. Kluger N, Salava A, Lybeck E, Kiiski LL, Nuutinen P, Ruohoalho T, et al. Faecal calprotectin in hidradenitis suppurativa: a study of 55 patients. Eur J Dermatol. 2020;30(4):422-4. [Crossref]  [PubMed] 
  29. Adarsh MB, Dogra S, Vaiphei K, Vaishnavi C, Sinha SK, Sharma A. Evaluation of subclinical gut inflammation using faecal calprotectin levels and colonic mucosal biopsy in patients with psoriasis and psoriatic arthritis. Br J Dermatol. 2019;181(2):401-2. [Crossref]  [PubMed] 
  30. Polkowska-Pruszyńska B, Gerkowicz A, Rawicz-Pruszyński K, Krasowska D. The role of fecal calprotectin in patients with systemic sclerosis and small intestinal bacterial overgrowth (SIBO). Diagnostics (Basel). 2020; 10(8):587. [Crossref]  [PubMed]  [PMC] 
  31. Özşeker B, Şahin C, Özşeker HS, Efe SC, Kav T, Bayraktar Y. The role of fecal calprotectin in evaluating intestinal involvement of Behçet's disease. Dis Markers. 2016;2016: 5423043. [Crossref]  [PubMed]  [PMC] 
  32. Kim MJ, Kim JY, Kang M, Won MH, Hong SH, Her Y. Reduced fecal calprotectin and inflammation in a murine model of atopic dermatitis following probiotic treatment. Int J Mol Sci. 2020;21(11):3968. [Crossref]  [PubMed]  [PMC] 

.: Up To Date

.: Process List

Login



Contact


Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com